We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+75.99%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.76B
AUM Growth
+$607M
Cap. Flow
+$235M
Cap. Flow %
13.41%
Top 10 Hldgs %
43.13%
Holding
124
New
28
Increased
25
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$34.5M
2
CYTK icon
Cytokinetics
CYTK
+$28M
3
VTYX
Ventyx Biosciences
VTYX
+$19.1M
4
ROIV icon
Roivant Sciences
ROIV
+$17.8M
5
FBRX icon
Forte Biosciences
FBRX
+$17.3M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$66.7M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$56.3M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$42.8M
4
MRUS
Merus
MRUS
+$26.9M
5
SLNO
Soleno Therapeutics
SLNO
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.68%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
26
AnaptysBio
ANAB
$1.51B
$21.6M 1.23%
+444,692
New +$17.3M
CGEM icon
27
Cullinan Oncology
CGEM
$1.09B
$20M 1.14%
1,932,106
+1,668,289
+632% +$15M
QURE icon
28
CALL
uniQure
QURE
$2.74B
$19.1M 1.09%
+800,000
New +$30.9M
AVTX icon
29
Avalo Therapeutics
AVTX
$971M
$19.1M 1.09%
1,051,054
+44,837
+4% +$757K
NRIX icon
30
Nurix Therapeutics
NRIX
$2.37B
$18.4M 1.05%
967,620
– –
TSHA icon
31
Taysha Gene Therapies
TSHA
$1.63B
$18.1M 1.03%
3,300,000
+300,000
+10% +$1.46M
MDGL icon
32
Madrigal Pharmaceuticals
MDGL
$12.4B
$18.1M 1.03%
31,131
-83,869
-73% -$42.8M
SVRA icon
33
Savara
SVRA
$1.14B
$16.9M 0.96%
2,797,153
+1,297,153
+86% +$6.35M
PTGX icon
34
Protagonist Therapeutics
PTGX
$8.68B
$15M 0.86%
172,125
-48,475
-22% -$3.97M
CNTA
35
DELISTED
Centessa Pharmaceuticals
CNTA
$15M 0.86%
600,552
-506,610
-46% -$12.8M
ESTA icon
36
Establishment Labs
ESTA
$2.77B
$14.6M 0.83%
200,000
-110,000
-35% -$6.64M
ERAS icon
37
Erasca
ERAS
$6.63B
$14.5M 0.83%
3,900,000
-385,787
-9% -$1.08M
VERA icon
38
Vera Therapeutics
VERA
$2.65B
$12.7M 0.72%
250,000
-53,330
-18% -$1.89M
COGT icon
39
Cogent Biosciences
COGT
$6.56B
$12.4M 0.71%
+350,000
New +$9.84M
OVID icon
40
Ovid Therapeutics
OVID
$435M
$11.7M 0.66%
7,150,000
+4,500,000
+170% +$6.93M
TVTX icon
41
Travere Therapeutics
TVTX
$5.17B
$11.5M 0.65%
300,000
-200,000
-40% -$6.5M
JBIO
42
Jade Biosciences
JBIO
$1.19B
$11M 0.63%
714,956
+649,639
+995% +$7.62M
NAMS icon
43
NewAmsterdam Pharma
NAMS
$3.48B
$9.65M 0.55%
275,000
– –
CLDX icon
44
Celldex Therapeutics
CLDX
$2.8B
$9.51M 0.54%
350,000
+50,000
+17% +$1.32M
ZURA icon
45
Zura Bio
ZURA
$503M
$9.5M 0.54%
1,813,671
+539,320
+42% +$2.13M
TNGX icon
46
Tango Therapeutics
TNGX
$4.52B
$8.86M 0.5%
+1,000,000
New +$8.62M
STRO icon
47
Sutro Biopharma
STRO
$373M
$8.66M 0.49%
748,382
+673,110
+894% +$6.39M
RVMD icon
48
Revolution Medicines
RVMD
$38.6B
$7.96M 0.45%
100,000
– –
MBX
49
MBX Biosciences
MBX
$2.89B
$7.88M 0.45%
250,000
+85,000
+52% +$2.06M
VRDN icon
50
Viridian Therapeutics
VRDN
$2.07B
$7.78M 0.44%
250,000
– –
1
2
3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Affinity Asset Advisors held 124 positions worth $1.76B, up 53% from $1.15B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $235M of net new capital in Q4 2025, opening 28 new positions and adding to 25 existing holdings. Its largest new stake was Praxis Precision Medicines: 185,000 shares worth $54.5M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $42.8M trimmed.

  • Affinity Asset Advisors's largest Q4 2025 buy was Praxis Precision Medicines: 185,000 shares worth $54.5M.
  • Affinity Asset Advisors added most to Cytokinetics in Q4 2025, an estimated $28M increase.
  • Affinity Asset Advisors's biggest Q4 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $42.8M.
  • Affinity Asset Advisors fully exited Verona Pharma in Q4 2025, selling an estimated $66.7M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $1.76B portfolio in Q4 2025.
  • Affinity Asset Advisors opened 28 new positions and closed 29 in Q4 2025.
  • Affinity Asset Advisors's portfolio value rose 53% quarter-over-quarter to $1.76B.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.